Claims

I/We claim:

1. A composition having antiviral activity for prophylaxis or treatment of flavivirus infection or a disease resulting therefrom in humans or animals, characterised in that the composition comprises quercetin, or analogues, or derivatives thereof.

2. The composition according to claim 1, wherein said quercetin is in a concentration range of 0.1 to 100% by weight.

3. The composition, according to claim 1, wherein the effective concentration of said composition is in a range of 29 µg/ml (28.8 µg/ml) – 35 µg/ml (35.7 µg/ml) of quercetin.

4. The composition, according to claim 1, wherein the composition formulated with a pharmaceutically acceptable carrier.

5. The composition, according to claim1, wherein the effective concentration of said composition having antiviral activity is 35.7 µg/ml of quercetin.

6. The composition, according to claim 1, wherein flavivirus comprises of dengue virus.

7. The composition, according to claim 1, wherein said composition is for the prophylaxis or treatment of dengue infection.

CLAIMS:

1. Use of a composition having antiviral activity comprising quercetin for the manufacture of a medicament for the prophylaxis or treatment of dengue virus in humans or animals, wherein the effective concentration of the composition is in the range of 29 µg/ml (28.9 µg/ml) to 35 µg/ml (35.7 µg/ml) of quercetin.

2. The use according to claim 1, wherein said quercetin is in a concentration range of 0.1 to 100% by weight.

3. The use according to claim 1, wherein the composition is formulated with a pharmaceutically acceptable carrier.

4. The use according to claim 1, wherein the effective concentration of the composition is 35.7 µg/ml of quercetin.

5. The use according to claim 1, wherein the dengue virus is selected from the group consisting of dengue virus type-1, dengue virus type-2, dengue virus type-3, and dengue virus type-4.

6. The use according to claim 1, wherein the dengue virus is dengue virus type-2.